NCT01670071View on ClinicalTrials.gov

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

PHASE4TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone extended-release

Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.

DRUG

Risperidone immediate-release

Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.

Trial Locations (3)

Unknown

Bali Township, Taipei County

Hualien City

Kaohsiung City

Sponsors
All Listed Sponsors
lead

Johnson & Johnson Taiwan Ltd

INDUSTRY